198 related articles for article (PubMed ID: 35800363)
21. Integrative Analysis of Neuregulin Family Members-Related Tumor Microenvironment for Predicting the Prognosis in Gliomas.
Zhao WJ; Ou GY; Lin WW
Front Immunol; 2021; 12():682415. PubMed ID: 34054873
[TBL] [Abstract][Full Text] [Related]
22. CKS2 (CDC28 protein kinase regulatory subunit 2) is a prognostic biomarker in lower grade glioma: a study based on bioinformatic analysis and immunohistochemistry.
Hu M; Li Z; Qiu J; Zhang R; Feng J; Hu G; Ren J
Bioengineered; 2021 Dec; 12(1):5996-6009. PubMed ID: 34494924
[TBL] [Abstract][Full Text] [Related]
23. The molecular feature of macrophages in tumor immune microenvironment of glioma patients.
Zhang H; Luo YB; Wu W; Zhang L; Wang Z; Dai Z; Feng S; Cao H; Cheng Q; Liu Z
Comput Struct Biotechnol J; 2021; 19():4603-4618. PubMed ID: 34471502
[TBL] [Abstract][Full Text] [Related]
24. Multicellular network-informed survival model for identification of drug targets of gliomas.
He X; Sun X; Shao Y
IEEE J Biomed Health Inform; 2023 Aug; PP():. PubMed ID: 37643106
[TBL] [Abstract][Full Text] [Related]
25. Screening TCGA database for prognostic genes in lower grade glioma microenvironment.
Ni J; Liu S; Qi F; Li X; Yu S; Feng J; Zheng Y
Ann Transl Med; 2020 Mar; 8(5):209. PubMed ID: 32309356
[TBL] [Abstract][Full Text] [Related]
26. Comprehensive Characterization of a Novel E3-Related Gene Signature With Implications in Prognosis and Immunotherapy of Low-Grade Gliomas.
Tan S; Spear R; Zhao J; Sun X; Wang P
Front Genet; 2022; 13():905047. PubMed ID: 35832194
[TBL] [Abstract][Full Text] [Related]
27. Comprehensive analysis of genes based on chr1p/19q co-deletion reveals a robust 4-gene prognostic signature for lower grade glioma.
Zhang C; Yu R; Li Z; Song H; Zang D; Deng M; Fan Y; Liu Y; Zhang Y; Qu X
Cancer Manag Res; 2019; 11():4971-4984. PubMed ID: 31213913
[No Abstract] [Full Text] [Related]
28. Prognostic value and immune relevancy of a combined autophagy-, apoptosis- and necrosis-related gene signature in glioblastoma.
Bi Y; Wu ZH; Cao F
BMC Cancer; 2022 Mar; 22(1):233. PubMed ID: 35241019
[TBL] [Abstract][Full Text] [Related]
29. Pyroptosis-Related Gene Signature Predicts Prognosis and Indicates Immune Microenvironment Infiltration in Glioma.
Zhang Y; Zhang C; Yang Y; Wang G; Wang Z; Liu J; Zhang L; Yu Y
Front Cell Dev Biol; 2022; 10():862493. PubMed ID: 35547808
[No Abstract] [Full Text] [Related]
30. Development of a Prognostic Five-Gene Signature for Diffuse Lower-Grade Glioma Patients.
Zhang Q; Liu W; Luo SB; Xie FC; Liu XJ; Xu RA; Chen L; Su Z
Front Neurol; 2021; 12():633390. PubMed ID: 34295296
[No Abstract] [Full Text] [Related]
31. A 63 signature genes prediction system is effective for glioblastoma prognosis.
Zhang Y; Xu J; Zhu X
Int J Mol Med; 2018 Apr; 41(4):2070-2078. PubMed ID: 29393370
[TBL] [Abstract][Full Text] [Related]
32. A Novel lncRNA Panel Related to Ferroptosis, Tumor Progression, and Microenvironment is a Robust Prognostic Indicator for Glioma Patients.
He Y; Ye Y; Tian W; Qiu H
Front Cell Dev Biol; 2021; 9():788451. PubMed ID: 34950662
[No Abstract] [Full Text] [Related]
33. A five-microRNA signature for individualized prognosis evaluation and radiotherapy guidance in patients with diffuse lower-grade glioma.
Zhang JH; Hou R; Pan Y; Gao Y; Yang Y; Tian W; Zhu YB
J Cell Mol Med; 2020 Jul; 24(13):7504-7514. PubMed ID: 32412186
[TBL] [Abstract][Full Text] [Related]
34. The proneural molecular signature is enriched in oligodendrogliomas and predicts improved survival among diffuse gliomas.
Cooper LA; Gutman DA; Long Q; Johnson BA; Cholleti SR; Kurc T; Saltz JH; Brat DJ; Moreno CS
PLoS One; 2010 Sep; 5(9):e12548. PubMed ID: 20838435
[TBL] [Abstract][Full Text] [Related]
35. Immune Infiltration-Related Signature Predicts Risk Stratification and Immunotherapy Efficacy in Grade II and III Gliomas.
Luo C; Liu Z; Ye W; Liu F
Front Cell Dev Biol; 2021; 9():756005. PubMed ID: 34805164
[No Abstract] [Full Text] [Related]
36. Identification of an Inflammatory Response-Related Gene Signature to Predict Survival and Immune Status in Glioma Patients.
Yan Z; Gao Y; Yu J; Shen Z; Bu X
J Immunol Res; 2022; 2022():8972730. PubMed ID: 35647198
[TBL] [Abstract][Full Text] [Related]
37. Systematic identification, development, and validation of prognostic biomarkers involving the tumor-immune microenvironment for glioblastoma.
Zhao B; Wang Y; Wang Y; Chen W; Liu PH; Kong Z; Dai C; Wang Y; Ma W
J Cell Physiol; 2021 Jan; 236(1):507-522. PubMed ID: 32572951
[TBL] [Abstract][Full Text] [Related]
38. Recurrence- and Malignant Progression-Associated Biomarkers in Low-Grade Gliomas and Their Roles in Immunotherapy.
Teng C; Zhu Y; Li Y; Dai L; Pan Z; Wanggou S; Li X
Front Immunol; 2022; 13():899710. PubMed ID: 35677036
[TBL] [Abstract][Full Text] [Related]
39. Comprehensive profiling identifies a novel signature with robust predictive value and reveals the potential drug resistance mechanism in glioma.
Zeng F; Wang K; Liu X; Zhao Z
Cell Commun Signal; 2020 Jan; 18(1):2. PubMed ID: 31907037
[TBL] [Abstract][Full Text] [Related]
40. Molecular Subtypes Based on the Stemness Index Predict Prognosis in Glioma Patients.
Tan J; Zhu H; Tang G; Liu H; Wanggou S; Cao Y; Xin Z; Zhou Q; Zhan C; Wu Z; Guo Y; Jiang Z; Zhao M; Ren C; Jiang X; Yin W
Front Genet; 2021; 12():616507. PubMed ID: 33732284
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
